Soleno Therapeutics, Inc. SLNO
$53.01
▲ +0.00% 24H
About
Soleno Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for rare diseases. Its primary product, VYKAT XR (diazoxide choline extended-release tablets), is an FDA-approved once-daily oral treatment for hyperphagia in patients aged 4 years and older w…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees182
TickerSLNO
Statistics
Market Cap$2.74B
Revenue (TTM)$282.8M
Net Income—
Net Margin—
EPS—
P/E27.47
P/S9.69
P/B6.16
EV/EBITDA27.99
ROE26.4%
Dividend Yield—
Price$53.01
Data: Twelve Data · Revenue = mcap / P/S